Update from ASH 2019 #2
Update from ASH 2019 #2
LYMPHOMA CONNECT has summarised the highlights from ASH 2019 for you. Highlights on Chronic Lymphocytic Leukaemia by Dr. Alexey Danilov, OHSU, Knight Cancer Institute, Portland, USA LYMPHOMA CONNECT has summarised the highlights from ASH 2019 for you. Highlights on Chronic Lymphocytic Leukaemia by Dr. Alexey Danilov, OHSU, Knight Cancer Institute, Portland, USADr. Jessica Okosun
Watch the video and download the slidesDr. Jessica Okosun
Clinician Scientist/Haematologist
Barts Cancer Institute and St Bartholomew's Hospital
United Kingdom (UK)
Dr Jessica Okosun is a Cancer Research UK Clinician Scientist at the Barts Cancer Institute and an Honorary Consultant Haematologist at St Bartholomew’s Hospital, London UK, specialising in lymphomas. She received her BA in Natural Sciences (Pathology) and qualified in medicine from the University of Cambridge in 2004. She was a recipient of the Kay Kendall Leukaemia Fund’s Junior Research Fellowship, completing her PhD in 2015 from Queen Mary, University of London. Her research interests are focussed on understanding the origin, heterogeneity and evolution of lymphomas, particularly follicular lymphomas, in a bid to define novel biomarkers and therapeutic strategies. Her research has led to several awards including the EHA/ASH Translational Research Training in Haematology award and the UK’s Royal College of Pathologist Specialty Research Medal in Haematology. She is an active member of the UK’s National Cancer Research Institute (NCRI) High Grade Lymphoma Subgroup, Hodgkin lymphoma subgroup and the Primary CNS Lymphoma (PCNSL) Working Party. She chairs the Barts Cancer Centre’s Patient and Public Research Advisory Group.
Dr. Jessica Okosun has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
| 5 min | 2019
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
LYMPHOMA & MYELOMA CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer and from Karyopharm Therapeutics.